Cargando…
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
We evaluated quality of life (QL) and quality-adjusted survival in International Breast Cancer Study Group Trial IX, a randomised trial including 1669 eligible patients receiving tamoxifen for 5 years or three prior cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 57 mon...
Autores principales: | Bernhard, J, Zahrieh, D, Coates, A S, Gelber, R D, Castiglione-Gertsch, M, Murray, E, Forbes, J F, Perey, L, Collins, J, Snyder, R, Rudenstam, C-M, Crivellari, D, Veronesi, A, Thürlimann, B, Fey, M F, Price, K N, Goldhirsch, A, Hürny, C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409769/ https://www.ncbi.nlm.nih.gov/pubmed/15545973 http://dx.doi.org/10.1038/sj.bjc.6602230 |
Ejemplares similares
-
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).
por: Bernhard, J., et al.
Publicado: (1998) -
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
por: Bernhard, J, et al.
Publicado: (2008) -
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
por: Colleoni, M, et al.
Publicado: (2002) -
Clinical relevance of single item quality of life indicators in cancer clinical trials
por: Bernhard, J, et al.
Publicado: (2001) -
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
por: Goldhirsch, A., et al.
Publicado: (2009)